Lilly's New Drug Yields Dramatic Weight Loss, Rivaling Bariatric Surgery, GLP-1s

Share on Pinterest A new experimental weight loss drug from Eli Lilly shows dramatic results that rival current GLP-1 drugs and bariatric surgery. Image Credit: Scott Olson/Getty Images Eli Lilly recently announced phase 3 trial results for a promising new weight loss drug retatrutide. The dramatic results from the TRIUMPH-1 trial represent the greatest weight loss observed in a medication trial, rivaling current GLP-1 drugs and bariatric surgery. Retatrutide is a triple hormone receptor agonist that activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Retatrutide led to significant improvements across various cardiovascular risk factors, including waist circumference, cholesterol, and blood pressure. Eli Lilly’s new experimental weight loss drug retatrutide showed the greatest weight loss in a medication trial to date. These numbers compare to participants who received a placebo and lost an average of 2.2%, or about 5.5 lbs. Incidents of dysesthesia and UTIs were generally mild to moderate. The majority of them resolved during treatment, and most participants continued taking retatrutide.